A comprehensive view of Branded Drugs. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Government & Public Policy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Fitch expects US sales of patented drugs to rise 5.3% year-over-year to US$327.3B in 2022, increase to US$371.9B in 2026; patented drug market is over four times the size of generic drug sub-sector, more than 10 times the size of OTC medicine sub-sector
Published: May 25, 2022 by Fitch Solutions Sector Intelligence
ViiV Healthcare announces FDA approval of Triumeq PD, a dispersible single-tablet treatment regimen for children living with HIV-1
Published: March 30, 2022 by GlaxoSmithKline PLC
Teva Pharmaceuticals announces settlement agreement with Attorney General of Florida related to opioid-related claims; Teva will pay US$177M over 15 years and will provide lifesaving Narcan nasal spray valued at US$84M over 10 years
Published: March 30, 2022 by Teva Pharmaceutical Industries Ltd.
AstraZeneca announces approval in Japan for Ondexxya for patients taking Factor Xa inhibitors, which help prevent blood clots but can lead to uncontrolled bleeding; Ondexxya quickly reverses Factor Xa inhibitors in patients experiencing acute bleeding
Published: March 29, 2022 by AstraZeneca AB
Takeda announces approval in Japan for TAKHZYRO subcutaneous injection for prevention of acute attacks of hereditary angioedema; condition is a rare genetic disorder that causes recurring swelling
Published: March 28, 2022 by Takeda Pharmaceutical Co. Ltd.

Ask us about our Government & Public Policy market view

Trending Chart

Interactive chart with headline count